START-UP VALUATION OF BIOTECH COMPANIES WITH REAL OPTIONS A case study of the start-up Organovo Holdings, Inc. Master Thesis HEC Paris Celine Göbel
[email protected] June 2016 ©2016 Celine Göbel. All rights reserved. The author hereby grants to HEC Paris permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part in any medium now known or hereafter created. Patrick Legland (Thesis Supervisor) Affiliate Professor in Finance at HEC Paris Start-up Valuation of Biotech Companies with Real Options A case study of the start-up Organovo Holdings, Inc. written by Celine Göbel Abstract: This master thesis examines several valuations methods for young companies. Start-ups are generally characterised by negative earnings, pure equity financing and binary business models. Traditional valuation methods, such as the Discounted Cash Flow, valuation multiples or comparable transactions, cannot be applied due to start ups’ high degree of uncertainty, short histories, volatile discount rates and little publicly available data on financials, comparable companies or comparable transactions. Consequently, new valuation methods, e.g. the Venture Capital method, the First Chicago method, the Damodaran approach and Real Option valuation, will be presented and directly applied to the 3D bioprinting start- up Organovo. The new valuation methods take the uncertainty of start-ups into account and allow more flexibility regarding timing and investment decisions. On top of this, the valuation of intangible assets is shortly discussed, as it is especially important for start-ups with a strong intellectual property portfolio. This master thesis also highlights non-financials factors in valuation, since the personal skills and experience of the founder and management team can have a large impact on the start-up’s value.